Handelsbanken Fonder Ab Gilead Sciences, Inc. Transaction History

Handelsbanken Fonder Ab

$25.3 Billion
Q3 2024

A detailed history of Handelsbanken Fonder Ab transactions in Gilead Sciences, Inc. stock. As of the latest transaction made, Handelsbanken Fonder Ab holds 538,703 shares of GILD stock, worth $49.9 Million. This represents 0.18% of its overall portfolio holdings.

Number of Shares

538,703

Previous 549,425 1.95%

Holding current value

$49.9 Million

Previous $37.7 Million 19.81%

% of portfolio

0.18%

Previous 0.16%

27 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Oct 04, 2024	SELL	$66.59 - $83.99 $713,977 - $900,540	-10,722 Reduced 1.95%	538,703 $45.2 Million
Q2 2024 Aug 05, 2024	BUY	$63.15 - $72.88 $3.19 Million - $3.68 Million	50,468 Added 10.11%	549,425 $37.7 Million
Q1 2024 May 13, 2024	SELL	$71.58 - $87.29 $5.24 Million - $6.39 Million	-73,235 Reduced 12.8%	498,957 $36.5 Million
Q4 2023 Feb 01, 2024	BUY	$73.27 - $83.09 $762,081 - $864,219	10,401 Added 1.85%	572,192 $46.4 Million
Q3 2023 Oct 19, 2023	SELL	$73.94 - $80.67 $1.05 Million - $1.15 Million	-14,268 Reduced 2.48%	561,791 $42.1 Million
Q2 2023 Aug 02, 2023	SELL	$76.01 - $86.7 $5.7 Million - $6.51 Million	-75,041 Reduced 11.53%	576,059 $44.4 Million
Q1 2023 Apr 28, 2023	BUY	$77.31 - $88.08 $1.33 Million - $1.52 Million	17,223 Added 2.72%	651,100 $54 Million
Q4 2022 Feb 07, 2023	BUY	$62.32 - $89.47 $9.09 Million - $13 Million	145,836 Added 29.88%	633,877 $54.4 Million
Q3 2022 Oct 27, 2022	BUY	$59.54 - $68.01 $3.61 Million - $4.12 Million	60,549 Added 14.16%	488,041 $30.1 Million
Q2 2022 Aug 03, 2022	BUY	$57.72 - $65.01 $5.65 Million - $6.37 Million	97,970 Added 29.73%	427,492 $26.4 Million
Q1 2022 May 11, 2022	BUY	$57.92 - $72.58 $986,145 - $1.24 Million	17,026 Added 5.45%	329,522 $19.6 Million
Q4 2021 Feb 08, 2022	SELL	$64.88 - $73.64 $733,208 - $832,205	-11,301 Reduced 3.49%	312,496 $22.7 Million
Q3 2021 Nov 10, 2021	BUY	$67.69 - $73.03 $25,992 - $28,043	384 Added 0.12%	323,797 $22.6 Million
Q2 2021 Aug 03, 2021	BUY	$63.47 - $69.35 $880,646 - $962,231	13,875 Added 4.48%	323,413 $22.3 Million
Q1 2021 Apr 29, 2021	SELL	$60.0 - $68.46 $2.86 Million - $3.26 Million	-47,588 Reduced 13.33%	309,538 $20 Million
Q4 2020 Feb 11, 2021	BUY	$56.65 - $64.55 $3.43 Million - $3.91 Million	60,630 Added 20.45%	357,126 $20.8 Million
Q3 2020 Nov 13, 2020	BUY	$62.1 - $78.08 $479,660 - $603,089	7,724 Added 2.67%	296,496 $18.7 Million
Q2 2020 Aug 13, 2020	BUY	$72.34 - $84.0 $20.9 Million - $24.3 Million	288,772 New	288,772 $22.2 Million
Q3 2019 Oct 31, 2019	SELL	$62.51 - $69.0 $6.2 Million - $6.84 Million	-99,157 Closed	0 $0
Q2 2019 Jul 12, 2019	SELL	$61.87 - $69.38 $4.3 Million - $4.82 Million	-69,495 Reduced 41.21%	99,157 $6.7 Million
Q1 2019 May 10, 2019	SELL	$62.53 - $70.05 $9.89 Million - $11.1 Million	-158,218 Reduced 48.4%	168,652 $11 Million
Q4 2018 Jan 31, 2019	BUY	$60.54 - $79.0 $199,782 - $260,700	3,300 Added 1.02%	326,870 $20.4 Million
Q3 2018 Oct 23, 2018	BUY	$71.28 - $78.92 $23.1 Million - $25.5 Million	323,570 New	323,570 $25 Million
Q3 2018 Oct 19, 2018	SELL	$71.28 - $78.92 $17.5 Million - $19.3 Million	-244,870 Closed	0 $0
Q2 2018 Jul 11, 2018	BUY	$64.88 - $75.68 $324,400 - $378,400	5,000 Added 2.08%	244,870 $17.3 Million
Q1 2018 May 18, 2018	BUY	$72.84 - $88.8 $2.84 Million - $3.46 Million	39,000 Added 19.42%	239,870 $18.1 Million
Q3 2017 Oct 24, 2017	BUY	$72.11 - $85.47 $14.5 Million - $17.2 Million	200,870	200,870 $16.3 Million

Others Institutions Holding GILD

# of Institutions

1,927

Shares Held

994M

Call Options Held

10.5M

Put Options Held

9.75M

View Full List

About GILEAD SCIENCES, INC.

Ticker GILD
Exchange NASDAQ
Sector Healthcare
Industry Drug Manufacturers—General
Shares Outstandng 1,253,369,984
Market Cap $116B
Description
Gilead Sciences, Inc., a biopharmaceutical company, discovers, develops, and commercializes medicines in the areas of unmet medical need in the United States, Europe, and internationally. The company provides Biktarvy, Genvoya, Descovy, Odefsey, Truvada, Complera/ Eviplera, Stribild, and Atripla products for the treatment of HIV/AIDS; Veklury, a...

More about GILD

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Handelsbanken Fonder Ab, based on Form 13F filings with the SEC.

News

Stay updated on Handelsbanken Fonder Ab with notifications on news.

Account

Handelsbanken Fonder Ab Gilead Sciences, Inc. Transaction History